Pursuing better treatments to help patients feel better, longer.
Bring your passion, join our team and make your mark.
Olema's latest news and recent events.
-
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Olema Oncology Announces New Clinical Trial Collaboration and Supply Agreement with Novartis in Frontline Metastatic Breast Cancer as well as $250 Million Equity Private Placement
-
Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium
-
Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
-
Olema Oncology to Participate in Upcoming Investor Conferences
-
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Olema Oncology Announces New Clinical Trial Collaboration and Supply Agreement with Novartis in Frontline Metastatic Breast Cancer as well as $250 Million Equity Private Placement
-
Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium
-
Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
-
Olema Oncology to Participate in Upcoming Investor Conferences
-
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Item 1 of 6